Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating expenses:
Research and development	$ 28,476,000	$ 17,498,000
General and administrative	13,550,000	11,659,000
Operating loss	(42,026,000)	(29,157,000)
Other income (expense), net:
Interest expense	(1,316,000)	(1,449,000)
Interest income and other income (expense), net	1,499,000	1,115,000
Other income (expense), net	183,000	(334,000)
Provision for income taxes	0	0
Net loss	$ (41,843,000)	$ (29,491,000)
Net loss per share of common stock and pre-funded warrants, basic	$ (1.5)	$ (1.91)
Net loss per share of common stock and pre-funded warrants, diluted	$ (1.5)	$ (1.91)
Weighted-average shares of common stock and pre-funded warrants outstanding, basic	27,901,739	15,416,203
Weighted-average shares of common stock and pre-funded warrants outstanding, diluted	27,901,739	15,416,203